Results 251 to 260 of about 753,720 (347)

Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

Arthritis &Rheumatology, EarlyView.
Objective Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc ...
Iqtidar Hanif, Shervin Assassi, Maureen D. Mayes, Zsuzsanna H. McMahan, Meng Zhang, Julio Charles, John M. VanBuren, Jessica S. Alvey, Kimia Ghaffari, Elana J. Bernstein, Flavia V. Castelino, Lorinda Chung, Luke Evnin, Tracy M. Frech, Jessica K. Gordon, Faye N. Hant, Laura K. Hummers, Dinesh Khanna, Kimberly S. Lakin, Dorota Lebiedz‐Odrobina, Yiming Luo, Ashima Makol, Jerry A. Molitor, Duncan F. Moore, Carrie Richardson, Nora Sandorfi, Ami A. Shah, Ankoor Shah, Victoria K. Shanmugam, Virginia D. Steen, Elizabeth R. Volkmann, Carleigh Zahn, Brian Skaug   +32 more
wiley   +1 more source

Cutaneous scalp metastasis from renal cell carcinoma with excellent response to chemotherapy. [PDF]

Skin Health Dis
Tan KW, Tan SH.
europepmc   +1 more source

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

Arthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun, Yu Wang, Yongjing Cheng, Dongmei Guo, Jiankang Hu, Dongzhou Liu, Zhengnan Gao, Changgui Li, Yibing Lu, Xiaodan Kong, Yu Liu, Zhenyu Jiang, Bin Yi, Hongfeng Zhang, Baijie Xu, Shihao Yu, Rieko Kokan, Kohei Ishikawa, Mikiko Kawakatsu, Zhuoli Zhang   +19 more
wiley   +1 more source

Upadacitinib in refractory cutaneous pseudolymphoma: A case report. [PDF]

SAGE Open Med Case Rep
Danese E, Curic T, Bellinato F, Colato C, Gisondi P, Girolomoni G.   +5 more
europepmc   +1 more source

Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective We used data from the placebo arm of the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD ...
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha Visvanathan   +6 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Post-inflammatory Pigmentary Alteration (PIPA)-Like Disorder Following COVID-19 Vaccination. [PDF]

Cureus
Bush LM, Fiallo PM, Vazquez-Pertejo MT.
europepmc   +1 more source

Pharmacodynamic Effects of Litifilimab in Lupus in the LILAC Phase II Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Arthritis &Rheumatology, Accepted Article.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from Part A (SLE) or Part B (CLE with/without SLE) of the randomized phase II LILAC trial who received ...
Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, Youmna Lahoud, Catherine Barbey   +8 more
wiley   +1 more source

Care and treatment for primary cutaneous lymphoma-associated ulcers: Two case reports. [PDF]

SAGE Open Med Case Rep
Wei M, Wei J, Li J, Li R, Liu J.
europepmc   +1 more source

Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways

Arthritis &Rheumatology, Accepted Article.
Background Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a ...
Gantsetseg Tumurkhuu, Graziela Perri, Richard Moore, Lihong Huo, Arati Naveen Kumar, Richard Ainsworth, Trinitee Oliver, Gabriela de los Santos, David Gibb, Jessica Carriere, Jeong Min Yu, Rachel Abuav, Lindsy Forbess, Daniel J. Wallace, Mariko Ishimori, Wonwoo Shon, Christian Stehlik, Caroline A. Jefferies   +17 more
wiley   +1 more source